Nanovi submits cancer biomarker for marketing approval in the US

Danish firm Nanovi has submitted its leading product, a biomarker for cancer therapies, for approval on the world’s biggest cancer market, where it has the potential to break new ground, says CEO Jesper Boysen.
Jesper Boysen, CEO of Nanovi | Photo: Nanovi / PR
Jesper Boysen, CEO of Nanovi | Photo: Nanovi / PR
by albert rønning-andersson, translated by daniel pedersen

Danish medtech firm Nanovi, whose chair of the board is Ambu heir Simon Hesse Hoffmann, has reached one of the bigger milestones in its history, which began in 2012 when the company was spun out from the Technical University of Denmark, DTU.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading